Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims are supported by the provided atorvastatin label excerpts (e.g., grapefruit juice interaction, muscle/myopathy warning, liver test monitoring). However, multiple safety/interaction statements about alcohol and the nature/timing of grapefruit/alcohol effects are not supported by the provided label text and may mislead; urgency/fever phrasing is also not reflected in the excerpts.
Category Scores
MonitoringRecommendations
90
Accurate Statements
Grapefruit and grapefruit juice can increase atorvastatin exposure by interfering with drug metabolism in the gut and liver.
Supported by: 7.2 Grapefruit Juice — grapefruit juice contains components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive consumption (>1.2 liters/day).
Avoiding grapefruit and grapefruit juice while taking atorvastatin is advised.
Partially supported by: 7.2 Grapefruit Juice — increased plasma concentrations especially with excessive grapefruit juice consumption. The label excerpt does not explicitly instruct complete avoidance, but supports caution/avoid excess.
Atorvastatin can cause muscle pain, tenderness, or weakness, which warrants urgent medical advice, especially if accompanied by fever or feeling very unwell.
Partially supported by: 5.1 Skeletal Muscle — myopathy defined as muscle aches or muscle weakness with CPK >10x ULN; label also states therapy should be temporarily withheld or discontinued in patients with acute, serious condition suggestive of myopathy. The excerpt does not mention fever/urgent advice wording.
Atorvastatin can be associated with signs of liver problems such as unusual fatigue, dark urine, or yellowing of the skin/eyes.
Partially supported by: 5.2 Liver Dysfunction — statins associated with biochemical abnormalities of liver function; however the label excerpt does not provide specific symptom examples like dark urine or jaundice.
For grapefruit, the interaction depends on the substance itself rather than a specific timing window.
Partially supported by: 7.2 Grapefruit Juice — describes inhibition of CYP 3A4 and increased plasma concentrations with excessive consumption; the excerpt does not specify a dosing-time window.
Most foods do not directly interact with atorvastatin in the way grapefruit does.
Not directly supported or contradicted by the provided excerpts; no label text addressed 'most foods' broadly.
Unsupported Statements
Increased atorvastatin exposure may raise the risk of muscle injury (myopathy/rhabdomyolysis) and other side effects.
The provided label excerpt states grapefruit juice can increase plasma concentrations of atorvastatin (7.2) and that statins can cause myopathy/rhabdomyolysis (5.1), but it does not explicitly link increased exposure from grapefruit to increased myopathy/rhabdomyolysis risk.
Alcohol plus statins can increase stress on the liver.
The provided label excerpts include liver dysfunction monitoring (5.2) but contain no statements about alcohol increasing liver stress in relation to atorvastatin.
Alcohol use with atorvastatin can be risky, especially with heavier or frequent use, because it can increase stress on the liver.
No alcohol-specific interaction/risk language is present in the provided label excerpts.
For alcohol, the issue depends on the amount and frequency rather than a single meal timing.
No alcohol-specific interaction or timing guidance is included in the provided label excerpts.
Most foods do not directly interact with atorvastatin in the way grapefruit does.
The provided label excerpts do not discuss other foods broadly or compare them to grapefruit.
Atorvastatin can cause muscle pain, tenderness, or weakness, which warrants urgent medical advice, especially if accompanied by fever or feeling very unwell.
While muscle aches/weakness are described, the excerpt does not include fever or 'urgent medical advice' phrasing.
Atorvastatin can be associated with signs of liver problems such as unusual fatigue, dark urine, or yellowing of the skin/eyes.
The excerpt discusses biochemical liver function abnormalities but does not list these specific clinical signs/symptoms.
Limiting or avoiding alcohol while taking atorvastatin is advised, particularly if the person has liver disease or abnormal liver tests.
No alcohol-avoidance recommendation or liver-disease/alcohol conditional language is included in the provided label excerpts.
Contradictions
Important Omissions
Grapefruit interaction guidance specificity: the label excerpt specifies 'especially with excessive grapefruit juice consumption (>1.2 liters per day)' rather than a general avoidance statement.
Importance:
Low
Liver monitoring details are not mentioned in the AI claims (pre-therapy, 12 weeks after initiation and after dose increases, and periodically thereafter).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Alcohol-related interaction and liver-stress claims are unsupported by the provided label excerpts; symptom/urgency phrasing is more specific than the excerpt supports. Grapefruit exposure increase claims are supported, but the interaction guidance is generalized.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Alcohol interaction and alcohol-avoidance recommendations are not supported by the provided FDA label excerpts; several clinical-sign/urgency details exceed the excerpt support.
Suggested Improvement
Remove or rephrase alcohol-related claims unless supported by additional label sections. For grapefruit, align wording to the label’s specific focus on CYP3A4 inhibition and increased plasma concentrations especially with excessive consumption (>1.2 L/day). Rephrase muscle/liver symptom urgency to match label language (myopathy defined by muscle aches/weakness with CPK >10x ULN; liver dysfunction described as biochemical abnormalities and monitoring).